Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/16459
Title: | Clinical outcomes in 995 unselected real-world patients treated with an ultrathin biodegradable polymer-coated sirolimus-eluting stent: 12-month results from the FLEX Registry |
Authors: | LEMOS, Pedro A.; CHANDWANI, Prakash; SAXENA, Sudheer; RAMACHANDRAN, Padma Kumar; ABHYANKAR, Atul; CAMPOS, Carlos M.; MARCHINI, Julio Flavio; GALON, Micheli Zanotti; VERMA, Puneet; SANDHU, Manjinder Singh; PARIKH, Nikhil; BHUPALI, Ashok; JAIN, Sharad; PRAJAPATI, Jayesh |
Citation: | BMJ OPEN, v.6, n.2, 2016 |
Abstract: | Objectives: To evaluate, in the FLEX Registry, clinical outcomes of an ultrathin ( 60 mu m) biodegradable polymer-coated Supraflex sirolimus-eluting stent (SES) for the treatment of coronary artery disease. Additionally, to determine the vascular response to the Supraflex SES through optical coherence tomography (OCT) analysis. Setting: Multicentre, single-arm, all-comers, observational registry of patients who were treated with the Supraflex SES, between July 2013 and May 2014, at nine different centres in India. Participants: 995 patients ( 1242 lesions) who were treated with the Supraflex SES, between July 2013 and May 2014, at nine different centres in India. A total of 47 participants underwent OCT analysis at 6 months' follow-up. Interventions: Percutaneous coronary intervention with Supraflex SES. Primary and secondary outcome measures: The primary endpoint-the rate of major adverse cardiac events ( defined as a composite of cardiac death, myocardial infarction (MI), target lesion revascularisation (TLR))-was analysed during 12 months. Results: At 12 months, the primary endpoint occurred in 36 (3.7%) of 980 patients, consisting of 18 ( 1.8%) cardiac deaths, 16 ( 1.6%) MI, 7 ( 0.7%) TLR and 2 ( 0.2%) cases of non-target lesion target vessel revascularization. In a subset of 47 patients, 1227 cross-sections ( 9309 struts) were analysed at 6 months by OCT. Overall, a high percentage of struts was covered ( 98.1%), with a mean neointimal thickness of 0.13 +/- 0.06 mu m. Conclusions: The FLEX Registry evaluated clinical outcomes in real-world and more complex cohorts and thus provides evidence that the Supraflex SEX can be used safely and routinely in a broader percutaneous coronary intervention population. Also, the Supraflex SES showed high percentage of stent strut coverage and good stent apposition during OCT follow-up. |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - HC/ICHC Artigos e Materiais de Revistas Científicas - HC/InCor Artigos e Materiais de Revistas Científicas - LIM/11 Artigos e Materiais de Revistas Científicas - LIM/13 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_LEMOS_Clinical_outcomes_in_995_unselected_realworld_patients_treated_2016.PDF | publishedVersion (English) | 924.48 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.